N/A
Completed N=36
Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections
Age-Related Macular Degeneration · Diabetic Macular Edema · Injection Site · Injection Site Infection
Source: ClinicalTrials.gov NCT02951351 ↗
Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcomePrimary: Number of Study Participants With Positive Conjunctival Culture — 1; 1 Participants — p=0.28
Summary
The specific aims of this study are to compare patient experience with and without a proparacaine drop after povidone iodine.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Study Participants With Positive Conjunctival Culture |
1; 1 | 0.28 |
| PRIMARY Pain at the Time of Injection |
2; 1 | 0.25 |
| SECONDARY Residual Pain From Intravitreal Injection |
1; 0 | 0.86 |
| SECONDARY Overall Impression of Visit for Intravitreal Injection |
0; 0 | 0.48 |
| SECONDARY Impression of Pre-injection Preparations |
0; 0 | 0.76 |
| SECONDARY Comfort With Intravitreal Injection Standard Procedure |
0; 0 | 0.31 |
| SECONDARY Expectation Intravitreal Injection Will Have Negative Consequences on Subject Health |
0; 0 | 0.18 |
| SECONDARY Expectation the Injection Will Contribute to Curing/Improving Eye Condition |
8; 10 | 0.67 |
Eligibility Criteria
Inclusion Criteria
- patients undergoing intravitreal injection who do not have active eye infections
- greater than 18 years of age
Exclusion Criteria
- patients younger than 18 years of age
- patients with active eye infections
Data sourced from ClinicalTrials.gov (NCT02951351). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.